Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
COLORECTAL: Metastatic: 1st Line Maintenance: LYNK-003

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)

Title
Merck MK7339-003 (LYNK-003, Colorectal)
Study Title

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)

Site Link
Malignancy
Colon, Rectal, Colorectal
Stage
Disease Setting
Metastatic/Palliative
Line Of Therapy
Maintenance (after 1st Line)
Investigational Agent
Olaparib + Bevacizumab
Drug Class
PARP inhibitor
PI
Axel Grothey, MD
Sponsor
Merck Sharp & Dohme Corp
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Metastatic or unresectable colorectal adenocarcinoma
  • Has not progressed after first-line induction of at least 6 cycles of FOLFOX with bevacizumab
    • May have received prior adjuvant/neoadjuvant chemo for CRC as long as it was completed at least 6 months prior to initiation of metastatic FOLFOX-bev
  • Has experienced unacceptable toxicity to oxaliplatin that required the discontinuation of oxaliplatin (such as neurotoxicity)
  • Must be randomized within a minimum of 2 weeks and a maximum of 6 weeks after their last dose of FOLFOX+bev
  • ECOG PS 0-1
  • No known CNS disease
  • No known HIV/HBV/HCV
  • No clinically significant bleeding within 28 days
  • No uncontrolled hypertension, nephrotic syndrome, GI perforation
  • No prior tx with olaparib or other PARP inhibitor
Objective
  • Primary
    • PFS
  • Secondary
    • OS
    • ORR
    • DoR
    • Safety
Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
Adenocarcinoma
Dosing Frequency
Control Agents
5-FU
Study Protocol
Randomized
Yes
X